期刊文献+

血清肿瘤标志物检测在肺癌诊断中价值 被引量:5

下载PDF
导出
摘要 目的探讨血清中癌胚抗原(CEA)、可溶性细胞角蛋白19片段(CYFRA 21-1)、神经元特异性烯醇化酶(NSE)、鳞状细胞癌相关抗原(SCC)浓度对肺癌的诊断、病理分型及临床分期的意义。方法选择经组织学和细胞学确诊的125例肺癌患者作为观察组,125例肺部良性病变患者作为对照组,分别测定两组患者血清中CEA、CYFRA 21-1、NSE、SCC的浓度。结果(1)观察组血清中四项肿瘤标志物浓度明显高于对照组(P〈0.01)。(2)腺癌血清CEA浓度最高,鳞癌血清CYFRA 21-1、SCC浓度最高,小细胞癌(SCLC)血清NSE浓度最高(P〈0.05)。(3)血清中四项肿瘤标志物浓度随肺癌TNM临床分期越晚浓度越高(P〈0.05)。(4)联合检测诊断肺癌的敏感性和准确性明显高于单项检测(P〈0.01),联合检测特异性下降,与CEA、CYFRA 21-1对比(P〈0.01)。结论血清中CEA、CYFRA 21-1、NSE及SCC的检测在肺癌的诊断、病理分型、判断预后有较好的临床价值,值得在临床上推广应用。 Objective To investigate the serum carcinoembryonic antigen(CEA),cytokeratin 19 fragment(CYFRA 21-1),neuron specific enolase(NSE),squamous cell carcinoma antigen(SCC)concentration in lung cancer diagnosis, pathological typing and clinical staging significance. Methods Select 125 cases of patients with lung cancer histology and cytology confirmed as the observation group,125 patients with benign pulmonary disease patients as control group,two groups of patients with serum CEA concentration in 21-1,CYFRA,NSE,SCC were measured. Results ①The observation group of four tumor markers in serum concentration was significantly higher than that of the control group(P〈O.01). ②The highest serum CEA concentration of adenocarcinoma,squamous cell carcinoma,the highest concentration of serum CYFRA21-1 SCC,serum SCLC NSE concentration was highest(P〈0.05). ③The serum levels of four tumor markers in lung cancer TNM concentration is higher in later clinical stages was higher(P〈0.05). ④The joint detection in diagnosis of lung cancer was significantly higher than that of the sensitivity and accuracy of the single detection(P〈0.01),the specificity of combined detection of CEA,CYFRA21-1 decreased,and the contrast(P〈0.01). Conclusion Pathological detection of SCC and CEA,CYFRA,21-1,NSE in serum in lung cancer diagnosis,classification,prognosis has good clinical value and is worth for clinical application.
出处 《浙江临床医学》 2013年第7期952-954,共3页 Zhejiang Clinical Medical Journal
关键词 肿瘤标志物 癌胚抗原 可溶性细胞角蛋白 神经元特异性烯醇化酶 鳞状细胞癌相关抗原 肺癌 诊断 Tumor marker Carcinoembryonic antigen Cytokeratin 19 fragment Neuron specificityenolase Squamous cell carcinoma antigen Lung cancer Diagnosis
  • 相关文献

参考文献8

  • 1Muley T,Fetz TH,Dienemann H,et al.Tumor volume and tumor marker index based on CYFR.A 21-1 and CEA are strong prognostic factors in operated early stage NSCLC.Lung Cancer, 2008, 60(3):408-415.
  • 2Swellam M,Ragab HM,Abdalla NA,et al.Soluble cytokeratin-19 and E-selecfin biomarkers: their relevance for lung cancer detection when tested independently or in combinatinis.Cancer Biomark,2008, 4(1):43-41.
  • 3Ebert W,Muley T,Trainer P,,et al.Comparison of changes in the NSE levels with clinical assessment in the therapy monitoring of patients with small cell lung cancer.Anticancer R.es,2002,22(28): 1083-1089.
  • 4Dabrowska M, Gmbek-Jaworska H, Domagata-Kulawik J, et al. Diagnostic usefulness of selected tumor markers(CA125,CEA,CYFRA 21-1)in bronchoalveolar lavage fluid in patients with non-small ceil lung cancer. Pol Arch Med Wewn,2004, 111 (6): 659-665.
  • 5Holdenrieder S,Von Pawel J,Duell T,et al.Clinical relevance of thymidine kinase for the diagnosis,therapy monitoring and prognosis of non-operable lung cancer.Anticancer P,.es,2010,30(5): 1855-1862.
  • 6Barl e si F,Gimenez C,Torre JP,et al.Prognostic value of combination of Cyfra 21-1,CEA and NSE in patients with advanced non-small cell lung cancer.Respir Med,2004,98(4):357-362.
  • 7Kagohashi K,Satoh H,Kurishima K,et al.Squamous cell carcinoma antigen in lung cancer and nonmalignant respiratory diseases.Lung, 2008, 186(5):323-326.
  • 8Oyama T,Osaki T,Baba T,et al.Molecular genetic tumor markers in non-small cell lung cancer.Anticancer Res,2005,25 (2B): 1193-1196.

同被引文献78

  • 1姜晓明,陈爽,杜晓艳,鞠晓红.5种血清肿瘤标志物检测在肺癌诊断中的临床价值[J].吉林医药学院学报,2013,34(2):81-84. 被引量:28
  • 2高云朝,王美琴,陆云,程伟,张学平,刘兴党,林祥通.血清肿瘤标志物的检测对肺癌患者的诊断价值[J].中华结核和呼吸杂志,2005,28(4):268-269. 被引量:32
  • 3郑智勇,卜宪敏,王晨,熊喜生,吴在增,余英豪.滤泡性淋巴瘤中C4d抗原沉积的意义[J].中华血液学杂志,2007,28(4):227-229. 被引量:2
  • 4罗杰,冷卫东.系统评价/Meta分析理论与实践[M].北京:军事医学科学出版社,2013.
  • 5Ajona D, Pajares MJ, Corrales L, et al. Investigation of complement ac- tivation product CAd as a diagnostic and prognostic biomarker for lung cancer[ J]. J Natl Cancer Inst ,2013,105 ( 18 ) : 1385-1393.
  • 6M-ikela K, Helen P, Haapasalo H, et al. Complement activation in as- trocytomas : deposition of C4d and patient outcome [ J ]. BMC Cancer, 2012,12:565.
  • 7Haidar F,Issa N. CAd deposits on erythrocytes (ECA-d) : a new bio- marker of antibody-mediated rejection in kidney transplantation [ J 1. Kidney Int, 2012,82 ( 4 ) :490 -491.
  • 8Kao AH,McBurney CA,Sattar A,et al. Relation of Platelet C4d with All-Cause Mortality and Ischemic Stroke in Patients with Systemic Lupus Erythematosus[ J]. Transl Stroke Res,2013,Epub ahead of print.
  • 9Roden AC, Scott JP, Jenkins SM, et al. C4d by Immunofluorescence and Immunohistochemistry in Routine Lung Allograft Biopsies [ J ]. The Journal of Heart and Lung Transplantation, 2013,32 (4) : S19- $20.
  • 10Golocheikine A, Nath DS, Basha HI, et al. Increased erythrocyte C4D is associated with known alloantibody and autoantibody markers of antibody-mediated rejection in human lung transplant recipients[ J]. J Heart Lung Transplant,2010,29(4) :410-416.

引证文献5

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部